Malaria remains one of Uganda’s leading causes of morbidity and mortality, particularly among vulnerable and underserved populations. Limited access to quality diagnostic testing and treatment, combined with low testing adherence, perpetuates the cycle of illness and prevents effective malaria control.

The Maisha Med Malaria Loyalty Project represented a strategic collaboration between CERAD and Maisha Med pharmaceutical supply to address these challenges. By enrolling 3,804 individuals in subsidized, high-quality malaria testing and treatment, the initiative enhanced access to affordable care, lowered malaria incidence, and improved community health outcomes.

This partnership leveraged Maisha Med’s pharmaceutical expertise and supply chain capabilities alongside CERAD’s community-based delivery model to create an integrated, data-driven approach to malaria prevention and treatment.